Drug Discovery and Development

  • Home Drug Discovery and Development
  • Drug Discovery
  • Women in Pharma and Biotech
  • Oncology
  • Neurological Disease
  • Infectious Disease
  • Resources
    • Video features
    • Podcast
    • Voices
    • Webinars
  • Pharma 50
    • 2025 Pharma 50
    • 2024 Pharma 50
    • 2023 Pharma 50
    • 2022 Pharma 50
    • 2021 Pharma 50
  • Advertise
  • SUBSCRIBE

An overview of common drug types: biologics, small molecules and cell/gene therapy

By Brian Buntz | January 24, 2023

The most common types of drugs in drug development are small molecules and biologics. Small molecules have a long history in the pharmaceutical industry and remain a pillar of modern medicine. 

Conversely, biologics are more complex molecules derived from living organisms. 

In this article, we provide a brief overview of common drug types, including biologics, small molecules, as well as cellular and gene therapy. 

Biologics

Biologic drugs are made from living cells. Biologics are more complex and larger than small-molecule drugs. Because biologics tend to be difficult to manufacture, they are also often expensive.

Biologics are made using a process called biomanufacturing. The first step of the process involves creating a cell blank. Next in the biomanufacturing process, a master cell bank yields a substantial number of genetically identical cells. 

Biologics  have considerable variability in type and can include vaccines, gene therapies and monoclonal antibodies. 

Recombinant DNA is a vital piece of biomanufacturing. Creating it involves isolating DNA from human cells, modifying it and eventually inserting it into a cell. 

As the Encyclopedia of Toxicology notes, recombinant DNA plays a vital role in the process as it helps construct the gene that is used to “express desirable qualities” in the target organism. 

Small molecules

Small molecule drugs are so-called because of their low molecular weight. While standards vary, small molecules tend to weigh less than 800 Daltons. Small molecule drugs are composed of simple chemical compounds that can bind to specific targets — often proteins — in the body to produce a therapeutic effect. In addition, small molecules’ compact size enables them to enter cells easily. Small molecules have a long history in the pharma industry and can be synthesized and manufactured in large quantities. 

Cellular and gene therapy 

Cell therapy, also called cellular therapy, involves using living cells to treat or prevent disease. Cells used in cellular therapy can be derived from the patient’s body (autologous cells) or donors (allogeneic cells). In addition, the technique can be used to replace or repair damaged tissue or cells. 

As the FDA notes, cellular therapy examples include immunotherapies, cancer vaccines and stem cell-based therapies. 

Gene therapy refers to delivering genetic material to cells to treat or prevent disease. The material is delivered to a cell via a vector, which are commonly engineered viruses bearing the therapeutic gene. After the gene therapy is delivered to target cells, it is incorporated into their DNA, producing a therapeutic protein or correcting a genetic defect. 

Gene therapy can be used to treat: 

  • Inactivate a disease-causing gene.
  • Correct genetic disorders resulting from mutations in a single gene.
  • Introducing a new gene. 

To date, the FDA has approved a relatively small number of cellular and gene therapy products.  

The agency notes that gene therapy is a type of biological product. 

One central cellular therapy, CAR-T, involves T cells, a type of lymphocyte that plays a vital role in the immune system. Chimeric antigen receptors (CAR) are receptor proteins genetically engineered to grant T cells the capability of homing in on a specific antigen to fight cancer. After CAR-T cells are produced in a lab, they are infused into a patient. To date, FDA has only approved a small number of CAR-T products, including Abecma (idecabtagene vicleucel), Breyanzi (lisocabtagene maraleucel), Kymriah (tisagenlecleucel), Tecartus (brexucabtagene autoleucel) and Yescarta (axicabtagene ciloleucel).

Another cellular therapy type, exosome therapy, involves using exosomes, small extracellular vesicles, to deliver therapeutic molecules to cells. A 2021 paper published in Stem Cell Investigation noted that exosomes “possess a higher therapeutic potential for various disease spectra due to their ability for intracellular shuttling.” The therapy, however, remains experimental, and the FDA notes that it has not approved any exosome products. 


Filed Under: Drug Discovery and Development

 

About The Author

Brian Buntz

As the pharma and biotech editor at WTWH Media, Brian has almost two decades of experience in B2B media, with a focus on healthcare and technology. While he has long maintained a keen interest in AI, more recently Brian has made making data analysis a central focus, and is exploring tools ranging from NLP and clustering to predictive analytics.

Throughout his 18-year tenure, Brian has covered an array of life science topics, including clinical trials, medical devices, and drug discovery and development. Prior to WTWH, he held the title of content director at Informa, where he focused on topics such as connected devices, cybersecurity, AI and Industry 4.0. A dedicated decade at UBM saw Brian providing in-depth coverage of the medical device sector. Engage with Brian on LinkedIn or drop him an email at bbuntz@wtwhmedia.com.

Related Articles Read More >

Collage of close-up male and female eyes isolated on colored neon backgorund. Multicolored stripes. Concept of equality, unification of all nations, ages and interests. Diversity and human rights
How a ‘rising tide’ of inclusivity is transforming clinical trials
Mary Marcus appointed CEO of NewAge Industries
DNA double helix transforming into bar graphs, blue and gold, crisp focus on each strand, scientific finance theme --ar 5:4 --personalize 3kebfev --v 6.1 Job ID: f40101e1-2e2f-4f40-8d57-2144add82b53
Biotech in 2025: Precision medicine, smarter investments, and more emphasis on RWD in clinical trials
Data analytics tools help doctors analyze trends in patient outcomes and population health.
External comparator studies: What researchers need to know to minimize bias
“ddd
EXPAND YOUR KNOWLEDGE AND STAY CONNECTED
Get the latest news and trends happening now in the drug discovery and development industry.

MEDTECH 100 INDEX

Medtech 100 logo
Market Summary > Current Price
The MedTech 100 is a financial index calculated using the BIG100 companies covered in Medical Design and Outsourcing.
Drug Discovery and Development
  • MassDevice
  • DeviceTalks
  • Medtech100 Index
  • Medical Design Sourcing
  • Medical Design & Outsourcing
  • Medical Tubing + Extrusion
  • Subscribe to our E-Newsletter
  • Contact Us
  • About Us
  • R&D World
  • Drug Delivery Business News
  • Pharmaceutical Processing World

Copyright © 2025 WTWH Media LLC. All Rights Reserved. The material on this site may not be reproduced, distributed, transmitted, cached or otherwise used, except with the prior written permission of WTWH Media
Privacy Policy | Advertising | About Us

Search Drug Discovery & Development

  • Home Drug Discovery and Development
  • Drug Discovery
  • Women in Pharma and Biotech
  • Oncology
  • Neurological Disease
  • Infectious Disease
  • Resources
    • Video features
    • Podcast
    • Voices
    • Webinars
  • Pharma 50
    • 2025 Pharma 50
    • 2024 Pharma 50
    • 2023 Pharma 50
    • 2022 Pharma 50
    • 2021 Pharma 50
  • Advertise
  • SUBSCRIBE